Thank you for stopping by! We have some common sense rules of play for our page community, spelled out below.
(285)
Wilmot Cancer Institute is a National Cancer Institute-Designated Cancer Center leading cancer care and research in 27 counties around Western and Central New York. By participating with URMC/Wilmot Cancer Institute in social networking communities, you agree to comply with these guidelines:
First, we ask that you treat others with respect, even if disagreements occur. Also, please do not post ma
terial that could be considered an infringement on the rights of others. URMC reserves the right to delete postings or off-topic comments, or block users, that it deems to be slanderous, obscene, soliciting, harassing, threatening, or otherwise contrary to these guidelines or UR policies. Remember that these are public forums and whatever information you share will be viewed by others. Consider this carefully before posting detailed personal medical information. Furthermore, the information provided by UR Medicine on these platforms is intended for educational purposes only. It is not intended as an endorsement, or a substitute for professional medical advice, diagnosis or treatment. If you are an employee of URMC, please remember that all laws and URMC policies apply, including but not limited to Privacy, HIPAA, Security and Safety. We suggest that you take time to review these policies. We encourage you to consult your manager if you have questions.
08/20/2025
Patients with low-grade astrocytoma, a type of brain tumor, now have a new treatment option: a targeted therapy called vorasidenib. It’s the first new treatment for this type of brain tumor in decades, and it has fewer side effects than other treatments.
Wilmot Cancer Institute’s Dr. Nimish Mohile helped write the new national guidelines for this new therapy, and several Wilmot patients are taking the drug.
Patients diagnosed with a type of brain tumor called an astrocytoma that tends to afflict younger adults.are benefitting from new approaches with fewer side effects.
08/11/2025
Members of our Blood & Marrow Transplant (BMT) and Cellular Therapies team were proud to gather with about 90 transplant survivors during our annual BMT Picnic this past weekend!
At the picnic, survivors ranged from a few months to 35 years out from their transplant, and every milestone in between. They traveled from destinations across upstate New York to celebrate survivorship and support others who have gone through a transplant.
"The picnic is a reminder of how fortunate we all are to have Wilmot Cancer Center in our community," shared Al Bushnell, who celebrated 14 years since his transplant for myelodysplastic syndrome. "Choosing Wilmot for my stem cell transplant was the best decision I could have made. I am especially grateful for Dr. Liesveld and her care team. They are the reason that I am still here enjoying a healthy and active life 14 years later."
Wilmot is home to the region’s first BMT program, and we’ve provided more than 4,700 transplants since our program began in 1989. BMTs are primarily used to treat blood cancers.
08/10/2025
Michelle Janelsins, PhD, has been a longtime Wilmot Warrior Weekend participant, helping to raise funds for cancer research and survivorship care at Wilmot.
Now, she's part of the research group (pictured here) that earned a Wilmot Warrior Weekend Team Science Award with funds raised through last year's event.
“It’s powerful to know that the funds we raise are helping drive research that could change lives," Janelsins says.
The research team will study cancer-related cognitive impairment (CRCI) - more commonly known as "chemo-brain" - among stage 3 and 4 lymphoma patients. Specifically, the team is working to better understand how circadian disruption (our body's "natural" sleep-wake cycle) and immune dysfunction impact this common side effect, in hopes of being able to develop ways to intervene and prevent or treat it.
Hundreds in our 27-county catchment area are diagnosed with bladder cancer each year, and Wilmot Cancer Institute is proud to be a leader in bladder cancer research and care.
In light of recent national news regarding bladder cancer, here are a few things everyone should know about the disease.
Pro Football Hall of Famer Deion Sanders Shared His Bladder Cancer Story: ‘Get Yourself Checked Out’
08/08/2025
When Nadine Poormon's multiple myeloma returned, she decided to join a clinical trial for CAR T-cell therapy.
Three years later, she is doing well and has had more time to experience many joys in life -- including watching her first grandchild grow up.
A new Wilmot Cancer Institute pilot study shows that women age 65 and older can safely leave the hospital on the same day after having a mastectomy for breast cancer after they have been properly screened for frailty and other conditions.
While the trend in reducing overnight hospital stays has been in effect for a while for younger people after a mastectomy, the Rochester study is unique because it focuses on older people, given frailty issues that could make recovery at home riskier.
Dr. Jessica Gooch was the first author on the study, which was published in the Annals of Surgical Oncology. Read more: https://urmc.info/29g
08/06/2025
We are proud to be designated by the National Cancer Institute!
The process to become an NCI-designated cancer center required not only talking with the community but bringing people like Karen Hermance into the fold, for two-way communication about community needs, research goals, and more. As co-chair of our Community Cancer Action Council (CCAC), Karen and other community members helped bridge Wilmot to our community, and that collaboration is an important component of why we got NCI designation.
Survivors Night with the Rochester Red Wings was an evening we won't forget. Thanks to all who made it possible. ❤️
Special shout-out to the UR teams and community organizations that joined us for the evening: Breast Cancer Coalition of Rochester, Cancer Support Community at Gilda's Club Rochester, Cancer Services Program of the Finger Lakes Region, graduate students from the University of Rochester School of Medicine & Dentistry, and more!
08/02/2025
Welcome to WCI Webster 👋
In celebrating our status as an NCI-designated cancer center, we traveled to each of our regional locations to spread the good news. We want you to get to know this team, too!
This is our newest outpatient location, and it’s quickly grown since opening in 2022. Many providers who see patients at Strong Memorial Hospital also come out to Webster to see patients, and they bring their multidisciplinary team with them. Patients can receive medical oncology, radiation oncology, and surgical consults all under one roof. Plus, patients at WCI Webster also have access to clinical trials, hereditary resources, social work, and more.
07/29/2025
The chemicals in black plastic have been linked to a variety of health concerns, including cancer. Some ways to limit exposure to black plastic include:
🥄Choosing wood or stainless steel utensils
🍲 Avoiding microwaving food in plastic containers
🖐️ Washing hands and wiping down surfaces after handling plastic packaging
Learn more about the research happening in this area at the University of Rochester ⤵️
Plastics in the kitchen may pose a risk, but their true health impact remains unclear. Researchers stress the need for more studies to understand how everyday plastic use affects our bodies.
07/26/2025
Waving from the west side at Strong West 👋
In celebrating our status as an NCI-designated cancer center, we traveled to each of our regional locations to spread the good news. We want you to get to know this team, too!
Located in Brockport, our Strong West location provides patients with medical oncology, hematology, and infusion services close to their home. Patients at Strong West also have access to clinical trials, hereditary cancer screening services, and more. We’re proud to serve our neighbors in Brockport and beyond!
Be the first to know and let us send you an email when Wilmot Cancer Institute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Wilmot Cancer Institute welcomes your participation on our page and encourages you to interact with us often and to comment about the content you find here.
We do not discriminate against any views, but administrators of official UR Medicine Wilmot Cancer Institute pages do reserve the right to delete the following or to block users who post the following:
Obscenity, nudity, defamation or hate speech (speech that targets people or groups based on race, ethnicity, religion, gender, or any other protected status.)
Comments/posts that threaten to harm individuals, groups, or organizations.
Commercial advertisements or solicitations of funds.
Endorsement or encouragement of illegal activities.
Multiple off-topic posts or repetitive posts that are copied and pasted.
Personal information including but not limited to email addresses, telephone numbers, mailing addresses, or identification numbers.
Remember that these are public forums and whatever information you share will be viewed by others. Consider this carefully before posting detailed personal medical information.
Furthermore, the information provided by Wilmot Cancer Institute on these platforms is intended for educational purposes only. It is not intended as an endorsement, or a substitute for professional medical advice, diagnosis or treatment.
If you are an employee of URMC/Wilmot, please remember that all laws and URMC policies apply, including but not limited to Privacy/HIPAA, Security and Safety. We suggest that you take time to review these policies and encourage you to consult your manager if you have questions.
